CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Biotechnology

Healthcare
$4.10 +2.42%

+$0.10 today

Market cap
$257.29M
Beta
0.08
P/E (TTM)
-2.8
EPS (TTM)
-$1.49
52W Low $1.31High $7.75

Volume 0.19M

Average 0.10M

CAMP Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

CAMP4 Therapeutics CorporationNASDAQ: CAMP

Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026

Depreciation & amortization growth accelerates

Q1 FY2026 depreciation & amortization of $520K rose 23.5% year over year, ahead of the +3.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 39.8% from the prior quarter.

Context

  • Depreciation & amortization amounted to 46.9% of revenue in FY2025, down 213.3 pp from a year earlier.
  • Depreciation & amortization increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +23.5% holds above the trailing-twelve-month pace of +3.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$520K+39.8% QoQ
Last fiscal yearDec 2025
$1.64M-3.4% YoY
LTMMar 2026
$1.74M+3.4% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+23.5%——
1 year-3.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
1.64M USD
Year-over-year change
-3.4%
4-year CAGR
-48.2%

Depreciation & Amortization vs competitors

How CAMP compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +3.4% is the 3rd highest of 9, against a peer median of -21.1%.
  • Depreciation & amortization amounts to 44.2% of revenue for CAMP, versus a peer median of 12.4%.
CAMP Competitors
Depreciation & Amortization for CAMP and competitors
Company Period LTM YoY 3-year CAGR% of revenue
VXRTVaxart, Inc.LTM Mar 2026$7.46M USD-16.4%+13.9%2.9%
HYFTMindWalk Holdings Corp.LTM Jan 2026CA$2.28M CAD-60.7%+10.7%12.4%
CAMPCAMP4 Therapeutics CorporationLTM Mar 2026$1.74M USD+3.4%—44.2%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$1.39M USD+27.4%+55.0%—
ATYRaTyr Pharma, Inc.LTM Mar 2026$1.34M USD+0.8%-2.9%705.3%
BMEABiomea Fusion, Inc.LTM Mar 2026$1.02M USD-43.2%+26.8%—
UNCYUnicycive Therapeutics, Inc.LTM Mar 2026$648K USD+144.5%+52.6%—
ALXOALX Oncology Holdings Inc.LTM Mar 2026$645K USD-25.8%+27.3%—
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$130K USD-84.1%-41.1%—
Peer median (excluding CAMP) —-21.1%+20.4%12.4%

Competitors are the stored peer set for CAMP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Feb 2022
FY2022
Feb 2023
FY2023
Nov 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue295.84M0350K652K3.5M
Cost of Revenue173.95M0001.64M
Gross Profit121.89M(947K)350K652K1.86M
Gross Margin41.2%—100.0%100.0%53.1%
Research & Development28.44M34.77M40.62M38.82M38.2M
Selling, General & Admin100.9M10.23M11.61M14.92M17.36M
Operating Expenses134.76M45M52.23M53.74M53.92M
Depreciation & Amortization22.8M878K1.68M1.7M1.64M
EBITDA7.49M(44.12M)(50.2M)(51.39M)(50.42M)
EBITDA Margin2.5%—-14343.1%-7882.2%-1441.5%
Operating Income(15.31M)(45M)(51.88M)(53.09M)(52.06M)
Operating Margin-5.2%—-14822.6%-8142.3%-1488.3%
Interest Income002.81M1.33M2.17M
Interest Expense15.32M6.26M000
Other Income / Expenses(14.75M)809K2.59M1.3M(28.34M)
Income Before Tax(30.06M)(44.19M)(49.29M)(51.79M)(80.4M)
Pre-Tax Margin-10.2%—-14083.1%-7943.4%-2298.5%
Income Tax Expense1.09M0000
Net Income(31.15M)(44.19M)(49.29M)(51.79M)(80.4M)
Net Margin-10.5%—-14083.1%-7943.4%-2298.5%
EPS (Basic)(0.88)(0.90)(4.07)(2.66)(2.65)
EPS (Diluted)(0.88)(0.90)(4.07)(2.66)(2.65)
Weighted Avg Shares35.25M36.1M12.12M19.51M30.38M
Weighted Avg Shares (Diluted)35.25M36.13M12.12M19.51M30.38M

CAMP4 Therapeutics Corporation

NASDAQ:CAMP

Intrinsic Alpha fair value

Locked

Current Price

$4.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.